Lebensqualität bei pulmonal arterieller und chronisch thromboembolischer pulmonaler Hypertonie

Halank, Michael; Speich, Rudolf; Petkova, D; Saxer, Stéphanie; Müller-Mottet, Séverine; Hasler, Elisabeth; Kolditz, Martin; Wilkens, Heinrike; Ehlken, Nicola; Lichtblau, Mona; Egenlauf, Benjamin; Kähler, C.; Lüneburg, Nicole; Mertens, Dirk; Schulz, Uwe; Barner, Andreas; Grünig, Ekkehard; Puhan, Milo A.; Ulrich, Silvia

doi:10.1055/s-0034-1387482

Cited by 2 publications

(2 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MLHF questionnaire consists of a general score (range 0-105), a physical subscore (range 0-40) and an emotional subscore (range 0-25), with higher scores reflecting poorer quality of life. In addition, we used the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) questionnaire specifically designed for PH, consisting of scales for symptoms (25 items), activity limitation (15 items) and quality of life (25 items), with a maximum score of 65 and likewise higher scores reflecting worse HRQoL [22,23,24]. …”

Section: Methodsmentioning

confidence: 99%

Prevalence of Anxiety and Depression in Pulmonary Hypertension and Changes during Therapy

et al. 2016

View full text Add to dashboard Cite

Background: Pulmonary hypertension (PH) leads to reduced health-related quality of life (HRQoL). Objective: To investigate the prevalence and course of anxiety and depression and their association with HRQoL, disease severity and survival in PH. Methods: 131 PH patients (91 pulmonary arterial, 30 chronic thromboembolic, 10 due to lung disease; 84 female, 47 male) had repeated assessments with the Hospital Anxiety and Depression Scale (HADS), HRQoL, six-minute walk distance and WHO functional class during a mean course of 16 ± 12 months. Results: Among the 49 incident and 82 prevalent PH patients, the HADS score was positive in 53%/21% (depression), 51%/24% (anxiety) and 63%/26% (total score) (all p < 0.05). The HADS score was improved at the second assessment in incident patients. The HADS score correlated with HRQoL at all consecutive assessments and with functional class until the third assessment, but not with baseline hemodynamics, age or gender. Conclusion: Mood disorders remain underdiagnosed in PH. The higher prevalence of anxiety/depression in incident versus prevalent patients and the improvement over time may indicate an amelioration of mood disorders after PH diagnosis and treatment.

show abstract

Section: Methodsmentioning

confidence: 99%

Prevalence of Anxiety and Depression in Pulmonary Hypertension and Changes during Therapy

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Comments: As impairment worsens, patients often develop depression and anxiety, which are found in 25-40% of PAH patients in WHO functional class (FC) III-IV [28][29][30]. These significantly reduce PAH patients' QoL and may also have a negative impact on both treatment adherence and the disease course.…”

Section: Psychological Supportmentioning

confidence: 99%

General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018

Grünig

Benjamin

Krüger

et al. 2018

International Journal of Cardiology

View full text Add to dashboard Cite

In the summer of 2016, delegates from the German Respiratory Society, the German Society of Cardiology and the German Society of Pediatric Cardiology met in Cologne, Germany, to define consensus-based practice recommendations for the management of patients with pulmonary arterial hypertension (PAH). These recommendations were built on the 2015 European Pulmonary Hypertension guidelines aiming at their practical implementation, considering country-specific issues, and including new evidence, where available. To this end, a number of working groups was initiated, one of which was specifically dedicated to general measures (i.e. physical activity/supervised rehabilitation, pregnancy/contraception, elective surgery, infection prevention, psychological support, travel) and supportive therapy (i.e. anticoagulants, diuretics, oxygen, cardiovascular medications, anaemia/iron deficiency, arrhythmias) for PAH. While the European guidelines provide detailed recommendations for the use of targeted PAH therapies as well as supportive care, detailed treatment decisions in routine clinical care may be challenging, and the relevance of supportive care is often not sufficiently considered. In addition, new evidence became available, thus requiring a thorough reevaluation of specific recommendations. The detailed results and recommendations of the working group on general measures and supportive therapy for PAH, which were last updated in the spring of 2018, are summarized in this article.

show abstract

Lebensqualität bei pulmonal arterieller und chronisch thromboembolischer pulmonaler Hypertonie

Cited by 2 publications

References 63 publications

Prevalence of Anxiety and Depression in Pulmonary Hypertension and Changes during Therapy

Prevalence of Anxiety and Depression in Pulmonary Hypertension and Changes during Therapy

General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018

Contact Info

Product

Resources

About